SCHEMBL7575780

SCHEMBL7575780

CCOC(=O)c1ccc(C#N)c(-c2ccccc2OC)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B2 P37059 1/20 0.51
KDM4E B2RXH2 3/20 0.48
CYP1A2 P05177 2/20 0.48
CYP3A4 P08684 2/20 0.48
CYP2C9 P11712 2/20 0.48
CYP2C19 P33261 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
RAB9A P51151 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
NPC1 O15118 2/20 0.47
HTT P42858 2/20 0.47
HSD17B10 Q99714 1/20 0.47
MAPT P10636 5/20 0.46
ALOX5 P09917 3/20 0.45
PTGES O14684 1/20 0.45
ALDH1A1 P00352 3/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
HCRTR1 O43613 1/20 0.44
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1369527 0.88 HSD17B2 (0.54) HSD17B2KDM4ECYP1A2CYP3A4CYP2C9
SCHEMBL2126994 0.87 SMN1; SMN2 (0.47) KDM4ERAB9ASMN1; SMN2NPC1HTT
SCHEMBL7571144 0.85 MAPT (0.47) HSD17B2KDM4ERAB9ASMN1; SMN2NPC1
SCHEMBL7571031 0.84 MAPT (0.49) KDM4ECYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL29900236 0.83 HSD17B2 (0.64) HSD17B2KDM4ECYP1A2CYP3A4CYP2C9
SCHEMBL4694878 0.83 HSD17B2 (0.60) HSD17B2KDM4ECYP1A2CYP3A4CYP2C9
SCHEMBL7571121 0.82 KDM4E (0.50) KDM4ECYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL6984418 0.82 MAPT (0.47) KDM4ENPSR1RAB9ASMN1; SMN2NPC1
SCHEMBL7571218 0.82 CDC25B (0.50) KDM4ERAB9ASMN1; SMN2HTTHSD17B10
SCHEMBL7569863 0.80 MAPT (0.46) KDM4ERAB9ASMN1; SMN2NPC1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020019527-A1 Substituted phenyl farnesyltransferase inhibitors ABBOTT LABORATORIES 2002-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019527-A1 Substituted phenyl farnesyltransferase inhibitors FNTA, FNTB, SLC10A1 HSD17B2 447/4885KDM4E 3715/4885CYP1A2 276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.